Alumis and Acelyrin have filed a definitive proxy statement/prospectus with the US Securities and Exchange Commission for the ...

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote “FOR” the merger Transaction expected to be ...

The joint proxy statement/prospectus are being mailed to all Alumis and ACELYRIN stockholders entitled to vote. Each company will hold a respective Special Meeting of Stockholders virtually at 12: ...

The joint proxy statement/prospectus are being mailed to all Alumis and ACELYRIN stockholders entitled to vote. With a team that has a successful track-record of developing innovative therapies ...

Alumis Inc. focuses on TYK2 inhibitors ESK-001 and A-005, with ESK-001 in Phase 3 for plaque psoriasis. Find out why ALMS ...

A potential buyer threatened to upend Alumis Inc.'s merger deal with Acelyrin Inc. as late as Monday, according to a Securities and Exchange Commission filings Thursday detailing the merger.